Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

G Raghu; J Behr; KK Brown; JJ Egan; SM Kawut; KR Flaherty; FJ Martinez; SD Nathan; AU Wells; HR Collard; U Costabel; L Richeldi; J De Andrade; N Khalil; LD Morrison; DJ Lederer; L Shao; X Li; PS Pedersen; AB Montgomery; JW Chien; TG O’Riordan; D Amin; A Baker; D Baratz; R Baughman; A Cagino; A Chan; J Chapman; F Cordova; J Edelman; R Enelow; N Ettinger; M Glassberg; J Golden; J Ilowite; M Kreider; S Kureishy; L Lancaster; D Lederer; A Limper; S Nathan; M Strek; M Padilla; M Fisher; D Riley; P Mohabir; Z Safdar; S Sahn; T Schaumberg; M Beth Scholand; C Smith; R Sussman; G Yung; R Saggar; J Zibrak; J Alvarez; K Chan; J Ruzi; J McConnell; J Mehta; G Verghese; A Talwar; T Haddad; N Sood; H Goldberg; K Sundar; T Ziedalski; K Gibson; C Chan; D Lien; C Fell; G Fox; C Poirier; S Provencher; P Wilcox; Z Vilayi-Weiler; M Kramer; M Yigla; A Baloira; J Behr; Z Parakova; Y Schwarz; C Martinez; I Ben-Dov; C Kahler; A Xaubet; J Skrickova; V Kolek; H Parfrey; J Echave-Sustaeta; W Wuyts; T Geiser; J Muller-Quernheim; M Whyte; M Pfeifer; C Grohe; LH Block

Journal article

Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

G Raghu, J Behr, KK Brown, JJ Egan, SM Kawut, KR Flaherty, FJ Martinez, SD Nathan, AU Wells, HR Collard, U Costabel, L Richeldi, J De Andrade, N Khalil, LD Morrison, DJ Lederer, L Shao, X Li, PS Pedersen, AB Montgomery Show all

Annals of Internal Medicine | Published : 2013

DOI: 10.7326/0003-4819-158-9-201305070-00003

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor. Objective: To determine whether ambrisentan, an ETA receptor-selective antagonist, reduces the rate of IPF progression. Design: Randomized, double-blind, placebo-controlled, eventdriven trial. (ClinicalTrials.gov: NCT00768300) Setting: Academic and private hospitals. Participants: Patients with IPF aged 40 to 80 years with minimal or no honeycombing on high-resolution computed tomography scans. Intervention: Ambrisentan, 10 mg/d, or placebo. Measurements: Time to dis..

View full abstract